Sentences with phrase «of pharmacogenomics»

His group also has a keen interest in developing National / Ethnic Genetic databases to document the genetic heterogeneity in different populations worldwide and to ascertain the impact of pharmacogenomics in healthcare professionals and the general public.

She collaborates for several years also with industry partners mainly in the field of Pharmacogenomics such as with Roche, Pfizer, Novartis, MSD or Bayer HealthCare and produced for them also HTA reports on health innovations.

George P. Patrinos currently serves as Associate Professor of Pharmacogenomics at the University of Patras (Greece), and since 2010, as expert and Greece's National representative at the CHMP Pharmacogenomics Working Party of the European Medicines Agency (London, UK).

Clinical application of pharmacogenomics knowledge will result in less «trial and error» prescribing and more efficacious, safer and cost - effective drug therapy.

The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe.

Economic Modeling: Our economic modeling core, led by Dr. Ann Wu, uses a variety of modeling approaches to project the medical and financial consequences of genomic medicine, including the use of pharmacogenomic testing to inform medication choices and the use of sequencing as an adjunct to standard newborn screening.

ePGA can be of benefit to health professionals, biomedical researchers and general public and may have a great impact in the clinic, even towards the use of a pharmacogenomics card / electronic health record.

Since 2013, he serves as Associate Professor of Pharmacogenomics at the University of Patras (Greece).

This working group is currently evaluating the impact of pharmacogenomic testing in reducing the healthcare costs of anticoagulation therapy and treatment for nicotine addiction, while these projects will soon be expanded in various healthcare systems to assess whether pharmacogenomics can indeed reduce the overall costs of these treatment modalities.

15:20 - 15:40 Genomic Medicine Sweden: Implementation of pharmacogenomics into clinical practice in Sweden

Such analyses are important in the area of pharmacogenomics.

The first part of the course includes an introduction to the discipline of Pharmacogenomics, accompanied by an historical perspective.

Lastly, this part summarizes the various regulatory aspects of pharmacogenomics and their role in drug development.

A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics.

The Section of Pharmacogenomics and Pharmacogenetics is a formal section of IUPHAR, a non-profit association representing the interests of pharmacologists throughout the world and whose mission is: Better Medicines through Global Education and Research.

Hakonarson H and Stefansson K Role of pharmacogenomics in drug development Drug Development Research 2004 62 (2): 86 - 96

Associate Professor, University of North Carolina, Institute of Pharmacogenomics and Individualized Treatment, Chapel Hill, NC, USA

He then joined Dr. Yuan - Tsong Chen's lab as a postdoc at Institute of Biomedical Sciences, Academia Sinica in Sept 2003 and was promoted to assistant director at the National Center for Genome Medicine (NCGM) from April 2004 and serves as the Director of the Pharmacogenomic Center in 2011 at Institute of Biomedical Sciences, Academia Sinica.

Notwithstanding, there are still barriers (scientific, economic, educational, ethical, legal) that need to be overcome prior to the application of pharmacogenomic technologies towards innovative clinical strategies and optimized therapeutic outcomes.

The third part of the course discusses the impact of population differences in the prevalence of pharmacogenomic biomarkers and their role in population pharmacogenomics.

Lastly, this part discusses the role and impact of Pharmacogenomics on public health.

Facilitate the introduction of pharmacogenomics and advanced omics technologies into the mainstream clinical practice.

Previous experience also includes a role as Senior Scientist with Eli Lilly and Company where she was part of the Pharmacogenomics and Translational Medicine Group in charge of discovering and validating genetic / genomic biomarkers in different therapeutic areas (oncology, cardio - metabolic and neurosciences).

Assessment of the Pharmacogenomics Educational Environment in Southeast Europe.

Economic evaluation of pharmacogenomics: a value - based approach to pragmatic decision making in the face of complexity.

The meeting will mark the official patnership with the Genomic Medicine Alliance and the SEAPharm Consortium and will focus on the recent trends in the field of Pharmacogenomics ad Personalized Medicine.

Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq / Nasdaq Europe: DCGN) today announced the signing of a pharmacogenomics agreement with Wyeth (NYSE: WYE).

American Journal of Pharmacogenomics.

With thousands of pharmacogenomic tests under development and many becoming available for clinical use, it is becoming increasingly important to understand the costs and benefits of these tests so that their potential for widespread use can be critically evaluated in ways that optimize their usefulness.

An electronic «pharmacogenomics assistant» (ePGA) to provide personalised drug recommendations based on linked genotype - to - phenotype pharmacogenomics data and support biomedical researchers in the identification of pharmacogenomic related gene variants has been developed.

«I have long been familiar with the common variations in response to drugs, but, like most physicians in my specialty, I had limited knowledge of the pharmacogenomics behind it, or the ability of this information to predict a problem.»

The growing field of pharmacogenomics — tailoring drugs based on an individual's genetic makeup — may need to take the microbiome into consideration.»

In 2009, he was appointed Assistant Professor of Pharmacogenomics at the University of Patras (Greece), and in 2010, he was appointed National representative at the CHMP Pharmacogenomics Working Party of the European Medicines Agency (London, UK).

There are currently three main areas defined where GENYO will perform its scientific activity: Area of Genomic Medicine, Area of Genomic Oncology and Area of Pharmacogenomics.

The first part of the course includes an introduction to bioinformatics the discipline of Pharmacogenomics, accompanied by an historical perspective.

The fifth and final part of the course is dedicated to the various ethical aspects of pharmacogenomics and the implications of the accompanying pharmacogenomics - related legislation.

Today, the Golden Helix Foundation and the Section of Pharmacogenomics and Pharmacogenetics of International Union of Basic and Clinical Pharmacology (IUPHAR) have entered into a collaborative agreement to foster their cooperation and to advance basic and clinical research in pharmacogenomics, its clinical translation and educational and learning activities.

Another found that only 13 percent of respondents felt well informed about the role of pharmacogenomics in therapeutic decision making.

The second part of the course includes examples from the clinical applications of pharmacogenomics.

And the field of pharmacogenomics, which was new when the research network began in 2000, has matured enough for its scientists to compete effectively with grant applicants in other fields, says Lorsch.

George P. Patrinos, Associate Professor of Pharmacogenomics and Pharmaceutical Biotechnology, University of Patras, Greece

Moderator: George P. Patrinos, Associate Professor of Pharmacogenomics and Pharmaceutical Biotechnology, University of Patras, Greece

He has published more than eighty peer - reviewed publications and book chapters in clinical pharmacology and pharmacogenomics, and he is the editor of three books in the field of pharmacogenomics.

Chair: George P. Patrinos, Associate Professor of Pharmacogenomics and Pharmaceutical BiotechnologyUniversity of Patras, Greece

The Golden Helix Foundation, recognizing the fact that the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public's awareness over the benefits of pharmacogenomics in rationalizing drug use, organized the 1st UPGx Personalized Medicine Public Day in London.